Literature DB >> 12934967

Diagnosis and treatment of Alzheimer's disease.

George T Grossberg1.   

Abstract

The defining characteristic of Alzheimer's disease is cognitive impairment, but commonly this impairment is accompanied by mood and behavioral symptoms such as depression, anxiety, irritability, inappropriate behavior, sleep disturbance, psychosis, and agitation. The symptoms of Alzheimer's disease are not normative to the aging process. Diagnosis of Alzheimer's disease in the majority of cases can be made with confidence through office-based clinical assessment and informant interview. Alzheimer's disease is the most common of the dementing disorders and is exponentially increasing in incidence, projected to affect 8.64 million people in the United States by the year 2047. At present, no treatment can prevent or cure Alzheimer's disease, and the fact that Alzheimer's affects a geriatric population makes treatment all the more challenging. Therapies that could delay onset of symptoms even briefly would have a major impact on public health. As the prevalence of Alzheimer's disease increases, researchers are examining the efficacy of treatment options beyond the realm of the established cholinesterase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934967

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Clinic visits and prescribing patterns among Veterans Affairs Maryland Health Care System dementia patients.

Authors:  G B Rattinger; C D Mullins; I H Zuckerman; E Onukwugha; S Delisle
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Poor dental hygiene and periodontal health in nursing home residents with dementia: an observational study.

Authors:  Andreas Zenthöfer; Dominik Baumgart; Tomas Cabrera; Peter Rammelsberg; Johannes Schröder; Nicoleta Corcodel; Alexander Jochen Hassel
Journal:  Odontology       Date:  2016-05-09       Impact factor: 2.634

3.  Caregiver burden, health utilities, and institutional service use in Alzheimer's disease.

Authors:  Edward Alan Miller; Robert A Rosenheck; Lon S Schneider
Journal:  Int J Geriatr Psychiatry       Date:  2011-05-10       Impact factor: 3.485

Review 4.  EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.

Authors:  Leon M Tai; Deebika Balu; Evangelina Avila-Munoz; Laila Abdullah; Riya Thomas; Nicole Collins; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  J Lipid Res       Date:  2017-04-07       Impact factor: 5.922

5.  A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 mice.

Authors:  Diane Jansen; Valerio Zerbi; Carola I F Janssen; Pieter J W C Dederen; Martina P C Mutsaers; Anne Hafkemeijer; Anna-Lena Janssen; Cindy L M Nobelen; Andor Veltien; Jack J Asten; Arend Heerschap; Amanda J Kiliaan
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

6.  Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AβPPswe-PS1dE9 mice.

Authors:  Diane Jansen; Valerio Zerbi; Ilse A C Arnoldussen; Maximilian Wiesmann; Anne Rijpma; Xiaotian T Fang; Pieter J Dederen; Martina P C Mutsaers; Laus M Broersen; Dieter Lütjohann; Malgorzata Miller; Leo A B Joosten; Arend Heerschap; Amanda J Kiliaan
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

7.  Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel.

Authors:  Abdalla Bowirrat; Jing Cui; Kristin Waraska; Robert P Friedland; Marlene Oscar-Berman; Lindsay A Farrer; Amos Korczyn; Clinton T Baldwin
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

Review 8.  Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.

Authors:  Daniel J Foster; Derrick L Choi; P Jeffrey Conn; Jerri M Rook
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-28       Impact factor: 2.570

9.  Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.

Authors:  Carina Wattmo; Elisabet Londos; Lennart Minthon
Journal:  BMC Neurol       Date:  2014-09-10       Impact factor: 2.474

Review 10.  Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection.

Authors:  Jimin Xu; Eric A Wold; Ye Ding; Qiang Shen; Jia Zhou
Journal:  Molecules       Date:  2018-02-22       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.